Edition:
United Kingdom

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

189.27USD
19 Oct 2017
Change (% chg)

$2.12 (+1.13%)
Prev Close
$187.15
Open
$185.00
Day's High
$190.57
Day's Low
$182.88
Volume
1,131,966
Avg. Vol
525,014
52-wk High
$256.78
52-wk Low
$182.88

Latest Key Developments (Source: Significant Developments)

Syndax Pharma enters into license agreement with unit of Allergan
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Syndax Pharmaceuticals :On Oct 13, co entered into license agreement with Vitae Pharmaceuticals, a subsidiary of Allergan Plc​ - SEC filing.Pursuant to agreement, co will make an upfront payment of $5.0 million to Allergan​.If parties commercialize Menin assets, co obligated to pay Allergan low single to low double-digit royalties on sales​.Under agreement, Allergan grants co worldwide license to portfolio of orally-available small molecule inhibitors of interaction of MLL protein​.Under agreement, may have to pay allergan up to $99 million in one-time development, regulatory milestone payments subject to achievement of milestones.In event of commercializing Menin assets, co to also pay up to $70 million in potential one-time sales-based milestone payments​.Company will be solely responsible for development and commercialization of Menin assets​.Under certain circumstances, co may be required to share a percentage of non-royalty income from sublicensees, with Allergan​.  Full Article

Syndax Pharmaceuticals says ‍expands pipeline with exclusive worldwide license to Allergan's portfolio of Menin-MLL inhibitors​
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Syndax Pharmaceuticals Inc ::Syndax Pharmaceuticals Inc - ‍expands pipeline with exclusive worldwide license to Allergan's portfolio of Menin-MLL inhibitors​.Syndax Pharmaceuticals Inc - ‍ entered into an exclusive worldwide license agreement with Vitae Pharmaceuticals, inc., a subsidiary of Allergan PLC​.  Full Article

U.S. Court issues adverse decision concerning Allergan's Restasis
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Allergan Plc :U.S. District Court for the Eastern District of Texas issues adverse trial decision concerning Restasis (cyclosporine ophthalmic emulsion) 0.05% patents.Says ‍company will appeal court's ruling regarding Restasis​.Says ‍"we are disappointed" by Federal District Court's decision on Restasis patents​.  Full Article

Orexigen announces favorable decision from U.S. court in patent litigation, confirming exclusivity for Contrave through 2030
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Orexigen Therapeutics Inc ::Orexigen announces favorable decision from U.S. District Court in patent litigation, confirming exclusivity for Contrave through 2030.Orexigen therapeutics - U.S. Court issued ruling in favor of Orexigen in litigation against Actavis Laboratories FL inc for three patents for Contrave​.  Full Article

Allergan announces settlement on Restasis patent litigation with Innopharma
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Allergan Plc :Allergan announces settlement on Restasis® (cyclosporine ophthalmic emulsion) 0.05% patent litigation with Innopharma, Inc..Allergan Plc - ‍additional details regarding settlement were not disclosed​.Allergan Plc - ‍as a result of settlement, all Innopharma Hatch-Waxman litigation regarding Restasis patents will be dismissed​.Allergan - will grant Innopharma licenses to market generic version of Restasis in U.S. beginning Feb 24, 2024, or earlier under certain circumstances​.Allergan - ‍under certain circumstances, co will supply, authorize Innopharma to launch an authorized generic version of Restasis on August 28, 2024​.  Full Article

BRIEF-Allergan says FDA accepts NDA for Ulipristal Acetate for Uterine Fibroids
Tuesday, 10 Oct 2017 

Repeats to widen distribution with no changes to text:Announces FDA accepts New Drug Application for Ulipristal Acetate for Uterine Fibroids.Expects Ulipristal Acetate Prescription Drug User Fee Act action date to occur in first half of 2018.  Full Article

Allergan says FDA accepts NDA for Ulipristal Acetate for Uterine Fibroids
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Allergan Plc ::Announces FDA accepts New Drug Application for Ulipristal Acetate for Uterine Fibroids.Expects Ulipristal Acetate Prescription Drug User Fee Act action date to occur in first half of 2018.  Full Article

Allergan USA files suits against Imprimis, Prescriber's Choice and Sincerus Florida
Friday, 8 Sep 2017 

Sept 7 (Reuters) - Allergan Plc :Allergan files suits against Imprimis Pharmaceuticals, Inc., Prescriber's Choice, Inc., and Sincerus Florida, LLC.Says Allergan USA filed lawsuits against Imprimis Pharmaceuticals, Prescriber's Choice, and Sincerus Florida.Allergan USA's lawsuit alleges that the companies are unlawfully manufacturing and selling unapproved new drugs.Lawsuit alleges that the co's are violating lanham act and state law by false and misleading advertising, promotion of unapproved new drugs.  Full Article

Zeltiq Aesthetics says upon termination of deal under specified circumstances co to pay Allergan Holdco US Inc termination fee of $74 mln
Wednesday, 15 Feb 2017 

Zeltiq Aesthetics Inc : On Feb 13, 2017 co entered into agreement and plan of merger with Allergan Holdco US, Inc. for $56.50 per share in cash .Under specified circumstances company may be required to pay Allergan Holdco US, Inc. a termination fee of $74 million - sec filing.  Full Article

Allergan says Goldman Sachs Group reported 6.3 pct passive stake in co as of Dec. 31 - SEC filing
Tuesday, 14 Feb 2017 

Allergan Plc :The Goldman Sachs Group Inc reports 6.3 percent passive stake in Allergan Plc as of dec. 31, 2016 - sec filing.  Full Article

UPDATE 2-Imprimis Pharma to take on Allergan's Restasis with cheaper product

Oct 19 Shares of Imprimis Pharmaceuticals Inc sky-rocketed as much as 91 percent on Thursday, after the company said it would launch a cheaper alternative to Allergan Plc's controversial dry eye drug, Restasis, by next month.